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abstract
PURPOSE The purpose of this study was to describe follow-up care for breast and colorectal cancer survivors in
countries with varying levels of resources and highlight challenges regarding posttreatment survivorship care.
METHODS We surveyed one key stakeholder from each of 27 countries with expertise in survivorship care on
questions including the components/structure of follow-up care, delivery of treatment summaries and survi-
vorship care plans, and involvement of primary care in survivorship. Descriptive analyses were performed to
characterize results across countries and variations between the WHO income categories (low, middle, high).
We also performed a qualitative content analysis of narratives related to survivorship care challenges to identify
major themes.
RESULTS Seven low- or /lower-middle-income countries (LIC/LMIC), seven upper-middle-income countries
(UMIC), and 13 high-income countries (HICs) were included in this study. Results indicate that 44.4% of
countries with a National Cancer Control Plan currently address survivorship care. Additional findings indicate
that HICs use guidelines more often than those in LICs/LMICs and UMICs. There was great variation among
countries regardless of income level. Common challenges include issues with workforce, communication and
care coordination, distance/transportation issues, psychosocial support, and lack of focus on follow-up care.
CONCLUSION This information can guide researchers, providers, and policy makers in efforts to improve the
quality of survivorship care on a national and global basis. As the number of cancer survivors increases globally,
countries will need to prioritize their long-term needs. Future efforts should focus on efforts to bridge oncology
and primary care, building international partnerships, and implementation of guidelines.
JCO Global Oncol 6:1394-1411. © 2020 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
The number of people living with and beyond a cancer
diagnosis has risen exponentially over the recent years
and is expected to continue to grow. In 2018, it was
estimated that 18.1 million new cases of cancer were
diagnosed throughout the world,1 with this number
expected to grow to 24 million by 2035.2 Moreover,
less-developed countries have recently experienced
large increases in the number of survivors as sys-
tematic efforts in screening and detection contribute to
earlier diagnosis and navigation to treatment.
Although advances in diagnostic and treatment capa-
bilities have improved cancer survival, the issues facing
people after completion of initial cancer treatment have
only more recently been recognized. Evidence demon-
strates that many cancer survivors are at increased
risk for late and long-term effects well after the end of
treatment, including cardiovascular disease, second
cancers, fatigue, and other physiologic and psychosocial
sequelae that impact quality of life,3 ability to return to
work,4 and increased costs to the health care system.5
Targeted interventions that address survivor needs have
been shown through numerous trials to improve many of
these issues.6,7 Overall, provision of survivorship care has
the potential to improve quality of life and functioning in
individual patients, result in improved health care utili-
zation, and potentially reduce morbidity and improve
survival through surveillance for recurrence and identi-
fying and addressing persistent issues.
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The US Institute of Medicine (IOM), now the National
Academy of Medicine, identified the following as important
components of posttreatment survivorship care:
1. Prevention and surveillance for recurrence and sub-
sequent primary cancers
2. Surveillance and management of physical and psy-
chosocial effects of cancer and its treatment
3. Health promotion and preventive care
4. Care coordination among providers and with survivors.8
Although there have been increasing efforts to enhance
survivorship care through international discussions and
collaborations,9,10 there is a lack of information on the delivery
of posttreatment follow-up care for survivors across a wide
range of countries. Previous research has focused on high-
income countries or is limited to one region.11 A recent review
on the state of survivorship care for childhood-onset cancers
across 18 countries highlighted challenges in communication
and coordination, particularly in the transition between pe-
diatric and adult care and among low-resource settings.12
By reviewing current practices and challenges in delivering
appropriate follow-up care for survivors of adult-onset can-
cers, particularly across low-, middle-, and high-income
countries, we can begin to understand commonalities and
variations. We recognize that under-resourced countries
may have competing priorities in the advancement of
cancer-related care. However, as under-resourced countries
increasingly adopt resource-stratified guidelines for the
treatment of cancer, there is a societal and ethical obligation
to initiate monitoring for recurrence and subsequent ma-
lignancies and management of long-term and late effects in
those who received treatment. Accordingly, collecting data
about the status of survivorship at the national level and
addressing survivorship care as part of a national cancer
control plan can help health care providers, researchers, and
policy makers in low-resource settings determine where
initial efforts in this area should be directed. For countries
with greater resources, this information can serve as foun-
dational for furthering the development of international
survivorship networks and dissemination and adoption of
evidence-based guidelines for survivorship care.
With these goals in mind, the purpose of this study was to:
(1) describe models of survivorship care from countries
with varying income levels, and (2) highlight challenges to
delivering posttreatment follow-up care for breast and
colorectal cancer survivors. Because it is likely that there is
great heterogeneity of survivorship care among cancer
sites, this survey targeted breast and colorectal cancers,
as these cancers are highly prevalent and guidelines for
follow-up care are established and available.13,14
METHODS
Identification of Countries and Stakeholders
To achieve a descriptive global survey, we used a conve-
nience sample method with an effort to include multiple
countries across different continents and with adequate
representation of low- and middle-income countries. One
stakeholder per country was selected based on their broad
understanding of survivorship care in their country and
their role in leading survivorship research and/or clinical
efforts at a government or institutional level. Of 28 national
stakeholders approached, 27 agreed to participate (96%).
Stakeholders were invited to complete a survey and asked
to provide a brief narrative on the challenges in delivering
posttreatment follow-up care in their country (survey can be
found in the Appendix). Stakeholders were asked to make
concerted efforts to determine that responses reflect the
pattern of care across the country.
All procedures performed in studies involving human
participants were in accordance with the ethical standards
of the institutional and/or national research committee and
with the 1964 Helsinki declaration and its later amend-
ments or comparable ethical standards.
Although we acknowledge different definitions of “cancer
survivor,” we asked stakeholders to reflect on care for those
who have completed active treatment with curative intent
and are in the posttreatment period. Stakeholders were also
asked to respond based on common practices for their
country, recognizing that there may be variability within
their country. The current survey was adapted from a
survey on models of care of childhood cancer survivors,12
CONTEXT
Key Objective
How is survivorship care for breast and colorectal cancer survivors delivered globally among low-, middle-, and high-income
countries?
Knowledge Generated
Results indicated great variation among countries regardless of income levels. Stakeholders reported challenges with
workforce capacity, communication and care coordination, and lack of focus on follow-up care.
Relevance
Attention to monitoring for recurrence, subsequent malignancies, and persistent issues for cancer survivors is essential to
maximize the benefits of curative and life-extending treatments.
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pilot tested with a subset of four countries, and then de-
livered electronically to all stakeholders.
Analysis
We categorized countries into the following groups: low/lower-
middle income (LIC/LMIC), upper-middle income (UMIC),
and high income (HIC), based on the World Bank classifi-
cation of economies to identify the income category for each
country.15 We performed a descriptive analysis of quantitative
survey items to describe frequencies and patterns by income
category. We analyzed the open-ended question on chal-
lenges to delivering survivorship care using a directed content
analysis approach.16 Two coauthors (M.A.M., S.S.B.) coded
each response by labeling or marking text segments with the
appropriate theme. The text segments were then reread, and
more fine-grained codes were developed.6 This process was
repeated until all the responses were assigned fine-grained
codes. Discrepancies in assignment of codes were resolved
through discussion and consensus.
RESULTS
Overview
The final sample included 27 countries from six continents and
consisted of seven LICs/LMICs, seven UMICs, and 13 HICs
(Fig 1). The stakeholders included clinicians (67.9%), re-
searcher/scientists (17.9%), and clinician researchers (14.3%)
with specific expertise in breast and colorectal cancer survi-
vorship care. Clinical disciplines included oncologists, psy-
chologists, social workers, and nurse practitioners.
Survey results varied greatly among countries, and, as
such, we report aggregate results in Tables 1-4 and indi-
vidual country data in Appendix Tables A1-A4. Below, we
highlight key findings across countries, as well as notable
differences by income category. Among the 22 countries
that have National/Governmental Cancer Control Plans
(NCCPs), survivorship care is included in 12 countries
(54.6%), is under development in five countries (22.7%),
and is not in development in five countries (22.7%).
Survivorship Care Delivery and Structure
Across countries, 24 (88.9%) use oncology-led follow up
care, and 12 (44%) use shared-care models with the
oncology team and general practitioner/primary care pro-
vider (GP/PCP; Table 1). Cancer-related follow-up care
is most often delivered through the treating institution
(74.1%; n = 20), whereas noncancer-related follow-up care
is most often delivered by a GP/PCP (48.1%; n = 13). We
found these patterns to be generally true for cancer-related
care in LICs/LMICs, UMICs, and HICs and for noncancer
LICs/LMICs and HICs. In contrast, the site where noncancer-
related follow-up care is delivered in UMICs is more variable,
where noncancer follow-up care is delivered mainly by the
treating institution in two countries (28.6%), by the GP/PCP
in two countries (28.6%), or with no formal follow-up care in
two countries (28.6%).
In 15 countries (55.6%), most clinicians use guidelines to
inform posttreatment follow-up care; the use of guidelines
varied by income level. Guideline were used in eight (61.5%)
of HICs, four (57.1%) of UMICs, and three (42.8%) of
Low/lower-middle income
country 
Upper-middle income country 
High-income country 
FIG 1. Countries included in global follow-up care for breast and colorectal cancer survivors survey (N = 27).
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TABLE 1. Survivorship Care Delivery
Care Delivery
Total
(N= 27)
Total
(%)
Total
LIC/LMIC
(n = 7)
LIC/LMIC
(%)
Total
UMIC
(n = 7)
UMIC
(%)
Total HIC
(n = 13)
HIC
(%)
Health care coverage
Universal 11 40.8 0 0 2 28.6 9 69.2
Mixed system, all survivors have coverage 4 14.8 1 14.3 1 14.3 2 15.4
Mixed system, most survivors have coverage 4 14.8 1 14.3 1 14.3 2 15.4
Mixed, many survivors do not have coverage 8 29.6 5 71.4 3 42.9 0 0
Cancer-related follow-up care
Treating institution 20 74.1 5 71.4 5 71.4 10 76.9
Mix of treating institution and GP/PCP 6 22.2 1 14.3 2 28.6 3 23.1
Most seen by GP/PCP 1 3.7 1 14.3 0 0 0 0
Many survivors receive no formal follow-up care 0 0 0 0 0 0 0 0
Noncancer-related follow-up care
Treating institution 3 11.1 1 14.3 2 28.6 0 0
Mix treating institution and GP/PCP 8 29.6 2 28.6 1 14.3 5 38.5
Most seen by GP/PCP 13 48.1 4 57.1 2 28.6 7 53.8
Many survivors receive no formal follow-up care 3 11.1 0 0 2 28.6 1 7.7
Models of follow-up care (check all)
Oncology 24 88.9 5 71.4 6 85.7 13 100
Primary care led 8 29.6 2 28.6 1 14.3 5 38.5
Shared care 12 44.4 3 42.9 2 28.6 7 53.8
Nurse led 5 18.5 1 14.3 0 0 4 30.8
Multidisciplinary survivorship clinic 6 22.2 2 28.6 0 0 4 30.8
None 1 3.7 0 0 1 14.3 0 0
Use of survivorship guideline
Almost all/most 15 55.5 3 42.8 4 57.1 8 31.5
About half 6 22.2 0 0 2 28.6 4 30.8
Some 3 11.1 3 42.9 0 0 0 0
Just a few 3 11.1 1 14.3 1 14.3 1 7.7
Primary source of guideline
Institution specific 2 7.4 0 0 2 28.6 0 0
National/international 11 40.7 3 42.9 3 42.9 5 38.5
Professional organization 5 18.5 1 14.3 1 14.3 3 23.1
Mixture of sources 9 33.3 3 42.9 1 14.3 5 38.5
Risk-based follow-up care
Almost all/most 5 18.5 0 0 1 14.3 4 30.8
About half 2 7.4 0 0 1 14.3 1 7.7
Some 8 29.6 4 57.1 2 28.6 2 15.4
Just a few 12 44.4 3 42.9 3 42.9 6 46.2
Lack of provider reimbursement as barrier
Very often/often 7 25.9 6 85.7 1 14.3 0 0
Occasionally 8 29.6 1 14.3 4 57.1 3 23.1
Some of the time 2 7.4 0 0 0 0 2 15.4
Rarely 10 37.0 0 0 2 28.6 8 61.5
(Continued on following page)
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LICs/LMICs. An additional item asked about risk-stratified
survivorship care that considers patients’ needs and their
complexity when deciding which survivors are seen at the
cancer center versus in the community. This approach to
care is used most of the time in only five (18.5%) of
countries, with four of these countries being HICs. Finally,
lack of reimbursement/compensation for follow-up care was
very often or often a barrier in seven (25.9%) of countries;
this was more often the case in LICs/LMICs (n = 6; 85.7%)
than UMICs (n = 1; 14.3%) and HICs (n = 0).
Treatment Summaries and Survivorship Care Plans
In 10 countries (37%), most survivors receive a written
summary of their cancer treatment, and in six countries
(22.2%), most survivors receive a written plan for posttreat-
ment follow-up care (ie, survivorship care plan [SCP];
Table 2). We found a consistent pattern across income cat-
egories for distribution of treatment summaries. In contrast,
the distribution of SCPs was more variable. In LICs/LMICs,
three (42.9%) of countries, and in HICs, three (29.7%),
provide care plans to most survivors. No UMICs report pro-
viding SCPs to most survivors. For those that provided SCPs,
key elements of posttreatment follow-up care most often in-
cluded prevention and surveillance for recurrence and new
cancers (n = 21; 77.8%) and surveillance and management
of physical effects of cancer and its treatment (n = 21; 77.8%).
Supportive Programs and Quality Metrics for Survivors
As shown in Table 3, the most frequent supportive re-
sources offered across countries are psychosocial support
(n = 21; 77.8%), self-management resources (n = 15;
55.6%), lifestyle change programs (n = 13; 48.1%), and
TABLE 1. Survivorship Care Delivery (Continued)
Care Delivery
Total
(N= 27)
Total
(%)
Total
LIC/LMIC
(n = 7)
LIC/LMIC
(%)
Total
UMIC
(n = 7)
UMIC
(%)
Total HIC
(n = 13)
HIC
(%)
Survivorship care part of NCCP
Yes 12 44.4 3 42.9 2 28.6 7 53.8
No, but in development 5 18.5 2 28.6 1 14.3 2 15.4
No, and not in development 5 18.5 1 14.3 3 42.9 1 7.7
No NCCP 5 18.5 1 14.3 1 14.3 3 23.1
Abbreviations: GP, general practitioner; HIC, high-income country; LIC/LMIC, low- and lower-middle-income country; NCCP, National Cancer
Control Plan; PCP, primary care provider; UMIC, upper-middle-income country.
TABLE 2. Treatment and Care Plans
Treatment and Care Plan
Total
(N = 27)
Total
(%)
Total
LIC/LMIC
(n = 7)
LIC/LMIC
(%)
Total
UMIC
(n = 7)
UMIC
(%)
Total HIC
(n = 13) HIC (%)
Written treatment summary to survivors
Almost all/most 10 37.0 3 42.9 3 42.9 4 30.8
About half 3 11.1 1 14.3 1 14.3 1 7.7
Some 6 22.2 0 0 1 14.3 5 38.5
Just a few 8 29.6 3 42.9 2 28.6 3 23.1
SCP to survivors
Almost all/most 6 22.2 3 42.9 0 0 3 23.1
About half 4 14.8 1 14.3 3 42.9 0 0
Some 6 22.2 1 14.3 2 28.6 3 23.1
Just a few 10 37.0 2 28.6 2 28.6 6 46.2
Key elements in SCPs (check all)
Prevention/surveillance for recurrence and new cancers 21 77.8 4 57.1 5 71.4 12 92.3
Surveillance/management of physical effects 21 77.8 6 85.7 5 71.4 10 76.9
Surveillance/management of psychosocial effects 5 18.5 2 28.6 0 0 3 23.1
Health promotion/disease prevention 10 37.0 4 57.1 2 28.6 4 30.8
Surveillance/management of chronic conditions 9 33.3 4 57.1 2 28.6 3 23.1
No SCPs 1 3.7 0 0 1 14.3 0 0
Abbreviations: HIC, high-income country; LIC/LMIC, low- and lower-middle-income country; SCP, survivorship care plan; UMIC, upper-
middle-income country.
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palliative care (n = 13; 48.1%). Five countries ( 18.5%) do not
offer any support programs or resources to survivors after the
completion of treatment. There are 10 countries (37%) that
currently do not use any metrics to evaluate the quality of
posttreatment follow-up care, including two LICs/LMICs, five
UMICs, and three HICs. Of those countries that do use
metrics, recurrence (n = 14; 51.9%), screening for recurrence
and subsequent primary cancers (n = 14; 51.9%), and
survivor symptoms (n = 12; 44.4%) were most often used.
Involvement of Nononcology Providers and
Communication Among Providers and Caregivers
Six countries (22.2%) have a national effort to educate GPs/
PCPs about the needs and care of cancer survivors
(Table 4). Of the remaining 21 countries, eight (38.1%)
have a plan in development and 13 (61.9%) do not have
a plan in development. Oncology teams and GPs/PCPs
communicate to share information about survivors often or
very often in six countries (22.2%). In eight countries
(29.6%), the treating institution sends a copy of the cancer
treatment summary to the GP/PCP most of the time or
almost always; this finding is mostly driven by HICs, which
comprise seven of the eight countries.
Challenges in the Delivery of Follow-Up Care
Several themes emerged from the qualitative analysis of
stakeholder narratives of challenges in posttreatment
follow-up care (Table 5). These include:
1. Workforce issues
2. Communication and care coordination
3. Access issues
4. Psychosocial support issues
5. Lack of focus on follow-up care.
Workforce issues included a shortage of providers, overload
in cancer centers, a lack of trained PCPs, and issues
with oncologists not sharing care with nononcology pro-
viders. Communication and care coordination issues in-
cluded breakdowns in connections between providers, no
streamlined communication between oncologists and
survivors, issues with technology, and lack of role de-
lineation with respect to the PCP. Access issues included
distance to facility and transportation challenges, re-
imbursement issues for providers who deliver survivorship
care, and financial costs to the survivor. Psychosocial
support issues are also a challenge, with stigma sur-
rounding psychosocial issues and lack of prioritization for
TABLE 3. Supportive Care and Quality Metrics for Evaluating Survivorship Care
Supportive Care or Quality Metric
Total
(N = 27)
Total
(%)
Total
LIC/LMIC
(n = 7)
LIC/LMIC
(%)
Total
UMIC
(n = 7)
UMIC
(%)
Total
High
(n = 13)
High
(%)
Supportive resources offered
Self-management 15 55.6 3 42.9 2 28.6 10 76.9
Psychosocial support 21 77.8 5 71.4 4 57.1 12 92.3
Lifestyle change programs 13 48.1 5 71.4 0 0 8 61.5
Online support/tools 8 29.6 2 28.6 1 14.3 5 38.5
Caregiver support 8 29.6 3 42.9 0 0 5 38.5
Complementary/integrative therapies 9 33.3 3 42.9 1 14.3 5 38.5
Palliative care 13 48.1 3 42.9 1 14.3 9 69.2
None 5 18.5 1 14.3 3 42.9 1 7.7
Metrics to evaluate survivorship care (check all)
Recurrence 14 51.9 4 57.1 2 28.6 8 61.5
Screening for recurrence/and subsequent cancers 14 51.9 4 57.1 2 28.6 8 61.5
Health-related quality of life 7 25.9 3 42.9 1 14.3 3 23.1
Patient-reported outcomes 4 14.8 2 28.6 0 0 2 15.4
Symptoms 12 44.4 4 57.1 2 28.6 6 46.2
Health status 9 33.3 2 28.6 2 28.6 5 38.5
Cost 1 3.7 0 0 0 0 1 7.7
Survivorship care plan delivery 2 7.4 0 0 0 0 2 15.4
Emergency department/urgent care visits 4 14.8 0 0 0 0 4 30.8
Adherence to care visits 7 25.9 2 28.6 1 14.3 4 30.8
Other 1 3.7 0 0 0 0 1 7.7
No metrics 10 37.0 2 28.6 5 71.4 3 23.1
Abbreviations: HIC, high-income country; LIC/LMIC, low- and lower-middle-income country; UMIC, upper-middle-income country.
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psychosocial care central to this theme. Finally, there was
a general lack of focus on follow-up care referenced. Two
countries noted that follow-up care is initiated by the patient
and they do not always see the need for continued care,
and others indicated that there was a general focus on the
treatment period and not on survivorship.
DISCUSSION
This study sought to examine the delivery of posttreatment
follow-up care for breast and colorectal cancer survivors
across the globe. Our results extend previous work focused
on single regions11 and high-income countries,17 which
highlighted barriers to advancing survivorship care. Of note,
we found that only 44.4% of 22 countries with an NCCP
currently address survivorship care. This is slightly higher
than a 2018 global analysis of NCCPs, which found that
32% of countries addressed survivorship in their NCCP.18
For those that do not have an NCCP, development of a plan
with a survivorship component may be a first step in im-
proving the quality of follow-up care.19 Below we offer
additional recommendations on the basis of our study
results.
Countries use several different models for the delivery of
posttreatment follow-up care, including oncology-led, PCP-
led, nurse-led, and shared care approaches as well as
multidisciplinary survivorship clinics. In the absence of
clear evidence supporting one model of survivorship
care over others,20 the model delivered is often based on
provider preferences, resources, and logistics. Although
several publications identify potential advantages of risk-
stratified21 and risk-based care,22 our results indicate that
this approach is used in only one-fifth of the countries
surveyed. One possible reason for this is the lack of con-
sensus for features included in risk stratification and lack of
readily available prediction models for key outcomes, al-
though efforts to predict risk for recurrence are underway.23
We recommend that countries begin by directing resources
toward surveillance for recurrence and second cancers for
those at highest risk.
Our results also indicated that in slightly more than half of
the countries, most clinicians use guidelines to inform
posttreatment follow-up care for breast and colorectal
cancer survivors. There was, however, less use of guide-
lines in LICs compared with UMICs and HICs. This situation
may reflect the fact that most guidelines are developed in
HICs and are designed for clinical settings that are often
well-resourced and do not explicitly consider the needs of
settings with fewer resources. Recognizing this situation,
a number of organizations have developed resource-
stratified guidelines that specify in an incremental man-
ner different levels of care for surveillance for recurrence,
second cancers, and persistent issues on the basis of
TABLE 4. Communication Between GPs/PCPs and Oncologists
Communication
Total
(N = 27)
Total
(%)
Total
LIC/LMIC
(n = 7)
LIC/LMIC
(%)
Total
UMIC
(n = 7)
UMIC
(%)
Total HIC
(n = 13) HIC (%)
National effort to educate GPs/PCP
Yes 5 18.5 2 28.6 0 0 3 23.1
No, but in development 8 29.6 2 28.6 0 0 6 46.2
No, and nothing in development 14 51.9 3 42.9 7 100 4 30.8
Treatment summary sent to GP/PCP
Almost always/most 8 29.6 0 0 1 14.3 7 53.8
About half of the time 1 3.7 1 14.3 0 0 0 0
Some of the time 5 18.5 3 42.9 0 0 2 15.4
Rarely 13 48.1 3 42.9 6 85.7 4 30.8
Survivorship care plan sent to GP/PCP
Almost always/most 3 11.1 0 0 0 0 3 23.1
About half of the time 2 7.4 0 0 1 14.3 1 7.7
Some of the time 7 25.9 4 57.1 1 14.3 2 15.4
Rarely 15 55.6 3 42.9 5 71.4 7 53.8
Oncologist and GP/PCP communicate regarding survivors
Very often/often 6 22.2 2 28.6 0 0 4 30.8
Occasionally 2 7.4 1 14.3 1 14.3 0 0
Some of the time 6 22.2 1 14.3 2 28.6 3 23.1
Rarely 13 48.1 3 42.9 4 57.1 6 46.2
Abbreviations: GP, general practitioner; HIC, high-income country; LIC/LMIC, low- and lower-middle-income country; PCP, primary care
provider; UMIC, upper-middle-income country.
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available resources. The Breast Health Global Initiative has
led one such effort, producing resource-stratified guide-
lines on breast health and cancer control, including sur-
vivorship and supportive care.24 Resource-stratified
guidelines in colorectal cancer, to date, have focused on
only early detection and treatment. Because the use of
guidelines may enhance the quality of survivorship care
and patient outcomes, our findings signal a need to con-
sider resource-stratified survivorship guidelines for other
cancer types.
The results of our survey showed that communication and
coordination between oncology and nononcology providers
and with patients and their families is a challenge for
countries regardless of income category, with few countries
reporting that oncologists and GPs/PCPs routinely com-
municate to share information. Our content analysis sup-
ported this finding, with stakeholders citing several issues
with communication, including a lack of role clarity, no
connection between the oncology team and GP/PCP, and
issues with technology. Although the use of an SCP was
recommended in the seminal IOM “Lost in Transition”
report,8 our results showed that in only six countries do
survivors routinely receive a written care plan for post-
treatment follow-up care. Previous research indicates that
implementation and evidence supporting SCPs has been
mixed25,26; however, the SCP may be a starting point to
enhancing coordination among providers. In addition, there
have been efforts by organizations such as the Cancer and
Research Primary Care International Network and ASCO to
bring together oncology and nononcology providers
through research and collaborative meetings. We recom-
mend continued efforts to bridge the persistent gap be-
tween oncology and primary care.
Another key strategy in improving survivorship care globally
is to systematically evaluate the quality of the care de-
livered. Our results indicate that 37% of countries do not
use any metrics to evaluate survivorship care, and among
those that do, almost all include recurrence and screening
for recurrence as a key metric. Although these are im-
portant metrics, survivorship care should be holistic and
often involves a multilevel evaluation of the comprehensive
components of care. A recent evidence-based framework
provides a starting point for future efforts to measure and
improve cancer survivorship care.27
It is also important to note that many stakeholders em-
phasized the role of nongovernmental organization (NGO)
support in survivorship and supportive care. Rehabilitation,
psychological support, and other efforts in these countries
may be driven by support from these organizations rather
than governmental or federal organizations. Future re-
search should include a global scan of the work of NGOs in
supportive survivorship care across countries from varied
income levels and health care systems.
This study provides critical data about posttreatment follow-
up care for cancer survivors, including broad representa-
tion of LICs/LMICs and UMICs. The results should be
viewed in light of certain caveats. First, findings are based
on the responses of a single stakeholder from each country,
each with different professional roles that may have af-
fected responses. Although the stakeholder was identified
as knowledgeable about survivorship efforts and encour-
aged to consult their peers, the extent to which these re-
sponses correspond to objective data on survivorship care,
assuming it could be collected, remains unknown. Limiting
each country to a single respondent also may obscure what
may be considerable within-country variation in survivor-
ship care. Regardless, this was an initial attempt to use key
stakeholders to characterize survivorship care globally. In
addition, although they have large and growing cancer
survivor populations, South America and Africa were rel-
atively under-represented continents in this study. Our
team did make efforts to identify stakeholders with ade-
quate expertise in other countries in these regions, how-
ever. Future work should continue to expand the evaluation
of survivorship care in other countries globally. Finally, the
number of countries surveyed was adequate to conduct
descriptive analyses, but we were not able to conduct in-
ferential statistical analyses based on income category.
Recognizing these limitations, future studies should focus
on identifying multiple stakeholders from each country to
better represent the variation within and among countries
and regions.
In summary, our findings identify several opportunities
for enhancing survivorship care on a global basis, in-
cluding the use of resource-stratified guidelines as well
as the inclusion of survivorship care in NCCPs. In ad-
dition, there is a need to increase efforts to improve
communication and coordination between oncology and
nononcology providers. We recognize that each country
may have different priorities for cancer control and that
efforts to improve screening and/or treatment outcomes
may be more pressing than a focus on survivorship care
in the context of limited health resources. As countries
invest in curative and life-extending cancer treatments,
however, attention to monitoring for recurrence and
subsequent malignancies is crucial if the benefits of
these investments are to be fully realized. In addition to
helping preserve treatment gains, the delivery of quality
follow-up care has the potential to address issues that
may affect survivors’ ability to return to work or resume
important social roles.
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TABLE 5. Themes of Challenges in Delivering Survivorship Care
Theme Subcategory Example Quote
References to Theme
LIC/LMIC UMIC HIC
Workforce issues Lack of providers,
nurses
The biggest challenge…is the skewed oncology professional to
patient ratio, which is not only very low, but is inequitably
distributed. [LIC/LMIC]
3 2 2
Overload in
cancer center
Posttreatment follow-up is not personalized to the risk of recurrent
disease and therefore the same for all breast cancer patients.
This is a burden to health care…because many women have
a low risk of recurrence. [HIC]
1 1 1
Lack of trained
GPs/PCPs
There is a lack of education about survivorship in both oncology
and primary care domains. [HIC]
2 3 3
No task sharing to
nononcology
providers
Oncologists work in silos, so there has not been task sharing or
shifting for follow-up care. [UMIC]
0 3 3
Communication
and care
coordination
Communication
between
providers
There is not routine connection between oncology team and GP/
PCP apart from discharged certificate with very short
information. [LIC/LMIC]
3 2 4
Issues with
technology
The intention is to establish a computer system with an electronic
file of the patient, to which both GPs and the oncologist have
access. [UMIC]
0 1 2
Role of PCP not
clear
The key elements of posttreatment follow-up care as well as
shared responsibilities aren’t defined clearly in national or
institutional guidelines/plans. [LIC/LMIC]
2 0 3
Communication:
provider-
patient
No streamlined channel of communication between oncologists
and survivors. [LIC/LMIC]
2 0 0
Access issues Distance/
transportation/
geography as
barrier
Majority of survivors have to gather at the treating institution or
cancer center for cancer-related follow-up care visits. This
creates dropping out of survivors who live in remote areas. [LIC/
LMIC]
2 1 0
Financial
concerns:
reimbursement
issues
Few incentives (carrots, sticks) to drive improved survivorship
care. [HIC]
3 2 2
Financial
concerns: cost
to survivor
The economic reality may interfere in the decision-making
process (for follow-up care) as when to attend to the doctor
against other basic needs such as roof, food, and taking care of
the needs of the family. [UMIC]
1 2 0
Psychosocial
support issues
Stigma with
psychosocial
issues
Many physicians, surgeons, and oncologists, don’t refer to mental
health practitioners for fear of the patient’s and/or family’s
reaction…Some med oncologists minimize psychological
reactions and symptoms of distress. [LIC/LMIC]
2 3 0
Not a priority The psychosocial issue among of cancer survivors is not
considered a priority. [HIC]
2 0 1
Lack of focus on
follow-up care
Follow-up care
initiated by
patient
Most of the survivors, once they complete their treatment, don’t
see any special need for coming for check-up…as such most
survivors come back as a result of recurrence. [LIC/LMIC]
2 0 0
Focus on
treatment
period/cure,
not survivorship
Emphasis remains primarily as care of new patients and their
management. [LIC/LMIC]
2 1 0
Need for patient
education
There are no campaigns focused on follow-up care, which
highlight the importance of attending to scheduled check-ups,
and little education is done related to healthy habits. [UMIC]
3 1 0
Abbreviations: GP, general practitioner; HIC, high-income country; LIC/LMIC, low- and lower-middle-income country; PCP, primary care provider; UMIC,
upper-middle-income country.
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APPENDIX
International Follow-Up Care for Breast and Colorectal
Cancer Survivors Survey Questions
1. What type of health care coverage do cancer survivors have in your
country? (please select one)
+ Universal or single payer health care system that covers all
cancer survivors
+ Mixed payer system but all cancer survivors have some type of
coverage
+ Mixed payer system with most, but not all, cancer survivors
having some type of coverage
+ Mixed payer system with many cancer survivors not having
coverage
2. What percentage of clinicians use guidelines to inform the
posttreatment follow-up care of breast and colorectal cancer
survivors? (please select one)
+ Almost all (. 90%)
+ Most (60%-89%)
+ About half (40%-59%)
+ Some (10%-39%)
+ Just a few (1%-10%)
+ None (please skip to question 4)
3. What is the primary source of guidelines used by clinicians for the
care of breast and colorectal cancer survivors? (please select one)
+ Institutional-specific set of guidelines
+ National or international guidelines
+ Professional organization guidelines (eg, ASCO)
+ Mixture of guideline sources
+ Other, please specify _____________________
4. Where are breast and colorectal cancer survivors seen for their
routine cancer-related follow-up care visits? (please select one)
+ ≥ 75% seen at the treating institution or a cancer center
+ Between 25% and 75% seen at treating institution/cancer
center and between 25% and 75% seen by a physician such as
a general practitioner (GP) or primary care provider (PCP), in
the community
+, 25% seen at the treating institution/ cancer center—most are
seen by physician in the community, such as a GP or PCP
+ , 25% seen at the treating institution/cancer center—many
survivors receive no formal cancer-related follow-up care
5. Where are breast and colorectal cancer survivors seen for their
routine noncancer-related follow-up care visits (including man-
agement of comorbid conditions)? (please select one)
+ . 75% seen at the treating institution or a cancer center
+ Between 25% and 75% seen at treating institution/cancer
center and between 25% and 75% seen by a physician such as
a GP or PCP, in the community
+, 25% seen at the treating institution/cancer center—most are
seen by physician in the community, such as a GP or PCP
+ , 25% seen at the treating institution/cancer center—many
survivors receive no formal noncancer-related follow-up care
6. What percentage of institutions in your country use pathways or
stratification based on patient needs and complexity when de-
ciding which breast and colorectal cancer survivors are seen at the
cancer center versus by physicians in the community? (please
select one)
+ Almost all (. 90%)
+ Most (60%-89%)
+ About half (40%-59%)
+ Some (10%-39%)
+ Just a few (, 10%)
7. What percentage of breast and colorectal cancer survivors in your
country receive a written summary of their cancer treatment?
(please select one)
+ Almost all (. 90%)
+ Most (60%-89%)
+ About half (40%-59%)
+ Some (10%-39%)
+ Just a few (, 10%)
8. What percentage of breast and colorectal cancer survivors in your
country receive a written care plan for posttreatment cancer-
related follow-up care? (please select one)
+ Almost all (. 90%)
+ Most (60%-89%)
+ About half (40%-59%)
+ Some (10%-39%)
+ Just a few (, 10%)
9. What percentage of survivorship programs involve nurses, nurse
practitioners (NPs), and physician assistants (PAs) in providing
follow-up care for breast and colorectal cancer survivors? (please
select one)
+ Almost all (. 90%)
+ Most (60%-89%)
+ About half (40%-59%)
+ Some (10%-39%)
+ Just a few (1%-10%)
+ No nurses, NPs, or PAs involved in follow-up care for survivors
+ No survivorship programs
10. Is there a national effort to educate GPs/PCPs about the needs and
care of cancer survivors? (please select one)
+ Yes
+ No, but one is in development
+ No, and nothing is in development
11. In general, how often does the treating institution send a copy of
the cancer treatment summary to the GP/PCP? (please select one)
+ Almost always (. 90%)
+ Most of the time (60%-89%)
+ About half of the time (40%-59%)
+ Some of the time (10%-39%)
+ Rarely (, 10%)
12. In general, how often does the treating institution send a copy of
the posttreatment cancer-related follow-up care plan to the GP/
PCP? (please select one)
+ Almost always (. 90%)
+ Most of the time (60%-89%)
+ About half of the time (40%-59%)
+ Some of the time (10%-39%)
+ Rarely (, 10%)
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13. In general, how often do oncology teams and GPs/PCPs com-
municate to share information about breast and colorectal cancer
survivors? (please select one)
+ Very often (. 90% of cancer survivors)
+ Often (60%-89% of cancer survivors)
+ Occasionally (40%-59% of cancer survivors)
+ Some of the time (10%-39% of cancer survivors)
+ Rarely (, 10% of cancer survivors)
14. What are the key elements of posttreatment follow-up care for
breast and colorectal cancer survivors that oncology providers in
your country routinely include in their follow-up care plans? (select
all that apply)
+ Prevention and surveillance for recurrence and new cancers
+ Surveillance and management of physical effects of cancer and
its treatment
+ Surveillance and management of psychosocial effects of cancer
and its treatment
+ Health promotion and disease prevention
+ Surveillance and management of chronic medical conditions
+ Other: ________________________
+ No follow-up care plans
15. What models of posttreatment follow-up care are used in your
country? (select all that apply)
+ Oncology-led follow-up care
+ Primary care–led follow-up care
+ Shared care (follow-up care is partnership between oncology
team and primary care provider)
+ Nurse-led follow-up care
o Multidisciplinary survivorship clinic (care provided by a spe-
cialized team [ie, oncologist, psychologist, cardiologist, etc] in
a separate clinical area)
+ Other: _____________________________
+ None
16. Are any of the following metrics used in your country to evaluate
the quality of posttreatment follow-up care for breast and co-
lorectal cancer? (select all that apply)
+ Recurrence
+ Screening for recurrence and second cancers
+ Health-related quality of life
+ Patient-reported outcomes and experiences of care
+ Symptoms
+ Health status
+ Cost
+ Delivery of a survivorship care plan
+ Emergency Department/ urgent care visits
+ Adherence to prescribed care visits/appointments
+ No metrics currently used to evaluate the quality of posttreat-
ment follow-up care
17. How often is lack of provider reimbursement/compensation for
posttreatment follow-up care for breast and colorectal survivors
a barrier to deliver these services? (please select one)
+ Very often (. 90% of cancer survivors)
+ Often (60%-89% of cancer survivors)
+ Occasionally (40%-59% of cancer survivors)
+ Some of the time (10%-39% of cancer survivors)
+ Rarely (, 10% of cancer survivors)
18. What support programs/resources are made available to breast
and colorectal cancer survivors after treatment ends? (please
select all that apply)
+ Self-management resources (for example: tools to provide
survivors with information, advice and support to enable them
to adapt to their condition)
+ Psychosocial support (for example: counseling, support groups)
+ Lifestyle change programs (for example: diet, exercise, smoking
cessation)
+ Online support/tools
+ Support for caregivers
+ Complementary or integrative therapy (for example: yoga,
acupuncture)
+ Palliative care program
+ None
19. How often do oncology teams and GPs/PCPs communicate with
family members as part of the patient’s follow-up care? (for ex-
ample: addressing survivorship care needs)
+ Almost always (.90%)
+ Most of the time (60%-89%)
+ About half of the time (40%-59%)
+ Some of the time (10%-39%)
+ Rarely (,10%)
20. Is care for cancer survivors part of your country’s National/Gov-
ernmental Cancer Control Plan? (please select one)
+ Yes
+ No section on care for cancer survivors in National Cancer
Control Plan, but one is in development
+ No section on care for cancer survivors in National Cancer
Control Plan, and nothing is in development
+ No National Cancer Control Plan
21. Please tell us about the challenges in posttreatment follow-up care
specific to country/survivor population.
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